Samsung Biologics's largest shareholder, a special account of an insurance company, net-sold 1,492 shares between September and October, reducing its stake from 74.30% to 74.29%, a decrease of 0.01 percentage points.

According to Samsung Biologics's report on changes in major shareholder holdings, the shares held by the special account decreased by a net 1,492 shares during the period from September 7 to October 2. Accordingly, the special account's stake decreased from 34,393,138 shares (74.30%) to 34,391,646 shares (74.29%). Currently, Samsung C&T is the largest shareholder with 43.06%, Samsung Electronics holds 31.22%, and the special account holds 0.01%.

1. 01

   The special account sold a net 1,492 shares through on-exchange trading between September 7 and October 2.

2. 02

   Samsung C&T is the largest shareholder of Samsung Biologics, holding 43.06%.

3. 03

   The combined stake of 3 Samsung-affiliated companies (Samsung C&T, Samsung Electronics, and the special account) is 74.29%.

4. 04

   The reporting company has 46,290,951 shares outstanding.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Previous holdings (September 7, 2026)

34,393,138 shares (74.30%)

Current holdings (October 6, 2026)

34,391,646 shares (74.29%)

Change in shares

-1,492 shares (-0.01%)

Samsung C&T stake

19,932,350 shares (43.06%)

Samsung Electronics stake

14,449,944 shares (31.22%)

Filing facts

Filing type

Largest Shareholder Holding Change

Report name

Report on Changes in Shares Held by the Largest Shareholder and Related Parties

Filed

Oct 6, 2026

Receipt number

20261006800676